TrialBreast cancer research and treatment2021

A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer.

Otto Metzger Filho et al.PubMed ↗Publisher ↗

No numbers read from the abstract.